Background
==========

Pituitary tumours are common, with an estimated prevalence of 16.7% based on autopsy and radiologic studies ([@bib1]). The relative prevalence of adrenocorticotropin (ACTH)-secreting (corticotroph) tumours, or Cushing's disease, is only 2--% of pituitary adenomas ([@bib2]). Untreated Cushing's disease conveys significant morbidity and mortality, with a 5-year survival rate of 50% attributable to cardiovascular and metabolic complications ([@bib3]). Surgery is standard of care first-line treatment for corticotroph tumours ([@bib4]). Post-operative radiotherapy may be indicated for incomplete resection, local recurrence or persistent hormonal secretion, and this may occur in up to 20--30% of patients with Cushing's disease ([@bib4], [@bib5]). The combination of surgery and radiotherapy leads to normalisation of hormonal control in 54--75% and local tumour control in 83--100% of cases ([@bib6]). Medical therapy may be used as second-line therapy, or when awaiting effects of radiotherapy, and includes drugs targeted against the somatostatin receptor to inhibit ACTH secretion (pasireotide), dopamine receptor to inhibit ACTH secretion (cabergoline), glucocorticoid receptor (mifepristone), or adrenal glucocorticoid production (ketoconazole, metyrapone, osilodrostat) ([@bib5], [@bib6], [@bib7]). Bilateral adrenalectomy is indicated in refractory or life-threatening Cushing's disease when requiring rapid correction of hypercortisolism or when other therapies have failed, as in our case ([@bib5]).

Although undoubtedly an effective adjunct treatment in the treatment of pituitary tumours, radiotherapy may result in potential complications including hypopituitarism, optic neuropathy, stroke and secondary malignancies ([@bib6]).

Case presentation
=================

We report a case of a 37-year-old female diagnosed with presumed Cushing's disease in 1986 on the basis of clinical and biochemical hypercortisolism and suppressed cortisol levels on a dexamethasone infusion test. Pituitary imaging did not visualise a pituitary tumour, CT of abdomen and pelvis did not reveal an obvious ectopic tumour, and inferior petrosal sinus sampling was not performed. Nevertheless, the clinical picture was thought to be consistent with Cushing's disease, and the endocrinologist at the time made a decision for primary transsphenoidal surgery, which failed to demonstrate a corticotroph tumour. She then received adjunctive 5000 rad of EBRT due to persistent hypercortisolism several months post-operatively. She required subsequent medical therapy with ketoconazole to inhibit adrenal steroidogenesis for several years with variable control of hypercortisolism. Her treating endocrinologist advised for a bilateral adrenalectomy with prompt resolution of hypercortisolism. She was maintained on replacement glucocorticoid and mineralocorticoid therapy (prednisolone 6 mg daily and fludrocortisone 100 µg daily), as well as thyroxine 50 µg daily for central hypothyroidism. She was not on growth hormone replacement but did previously require estradiol replacement for several years.

Her other comorbidities included ischaemic heart disease with coronary artery stenting, hypertension, peptic ulcer disease, glucocorticoid-induced osteoporosis with vertebral fractures not on treatment, chronic pain, depression and a 40 pack-year smoking history. At age 67, she was brought to her regional emergency department following a witnessed generalised tonic-clonic seizure with prolonged post-ictal state. No other history was able to be elicited apart from progressive lethargy and possible alcohol excess prior to presentation. There was no past seizure disorder.

Investigations
==============

Laboratory investigations on admission identified a mixed respiratory and metabolic alkalosis (pH: 7.63, HCO~3~^−^ : 32 mmol/L, pCO~2~ : 26 mmHg). There was mild hyponatraemia (132 mmol/L (135--145)), hypokalaemia (3.2 mmol/L (3.2--5.0)), and renal impairment (creatinine: 79 µmol/L (60--110), estimated glomerular filtration rate: 67 mL/min/1.72 m^2^ (≥90)). Pituitary hormonal panel performed on the morning of day 3 of her admission was consistent with hypopituitarism. Her follicular stimulating hormone level and luteinising hormone levels were 1.3 IU/L (25.0--140.0) and \<0.5 IU/L (7.7--60.0), respectively, low in the setting of menopause. Thyroid function was consistent with central hypothyroidism with a thyrotrophin releasing hormone level of 0.04 mIU/L (0.40--4.20) and a normal free thyroxine of 17.5 pmol/L (11.0--22.0) on thyroxine replacement. Prolactin level was normal at 74 mIU/L (50--500). A serum cortisol level was 32 nmol/L (150--520) while receiving dexamethasone for several days. Unfortunately, no adrenocorticotrophic hormone level was obtained prior to the administration of dexamethasone. Growth hormone and insulin-like growth factor 1 were not measured. Her blood haematology, liver function tests, coagulation profile and C-reactive protein were within normal range.

MRI ([Fig. 1](#fig1){ref-type="fig"}) on presentation demonstrated an extracranial soft-tissue mass infiltrating the right temporal bone and involving both temporal and parietal lobes. Figure 1Brain MRI with gadolinium enhancement. (A) Coronal T1, (B) Axial T1, and (C) Axial T2 sections demonstrating a large mass effacing the right temporal bone, with evidence of fluid levels and haemorrhage. There is extensive perilesional oedema and compression of the temporal horn of the right lateral ventricle.

Treatment
=========

Based on the clinical presentation and CT findings, the patient was immediately commenced on oral dexamethasone 8 mg TDS to reduce cerebral oedema and levetiracetam 500 mg BD for seizure prophylaxis. She experienced further generalised tonic-clonic seizures on the medical ward, requiring IV midazolam and phenytoin, followed by emergency sedation and intubation. Repeat CT brain demonstrated haemorrhage into the intracranial component of the infiltrating mass, and the decision was made for urgent transfer to a tertiary intensive care unit with neurosurgical support on day 3. Medications on intensive care admission were intravenous dexamethasone 4 mg TDS, levetiracetam: 500 mg BD, thyroxine: 50 µg OD, fludrocortisone: 100 µg OD and thiamine: 100 mg OD (given the possibility of alcohol excess based on history). She required noradrenaline for inotropic support and exhibited a fluctuating level of consciousness and delirium. She was dependent on NG feeds and i.v. dextrose to maintain normoglycaemia. MRI brain ([Fig. 1](#fig1){ref-type="fig"}) demonstrated a large mass effacing the temporal bone with partial extra- and intracranial extension, extensive perilesional oedema and compression of the temporal horn of the right lateral ventricle. The radiological findings were most in keeping with osteosarcoma, although differential diagnoses included chondrosarcoma and haemangiopericytoma arising from the osseous vault. CT abdomen and pelvis did not yield evidence of metastatic or another source of primary malignancy (not shown).

On day 5 of admission, she underwent stereotactic resection of right temporal tumour and cranioplasty. A post-operative CT brain ([Fig. 2](#fig2){ref-type="fig"}) confirmed removal of the intracranial mass, although no attempt was made to completely excise all involved bone. Figure 2(A) Post-operative coronal and (B) axial CT sections indicating no post-operative haemorrhage, but persisting mass effect and cerebral oedema with effacement of the right cerebral sulci.

Outcome and follow-up
=====================

Extubation occurred on day 9 of admission, with transient improvement in neurological status and delirium, before the patient suffered a cardiac arrest from a likely aspiration event on day 12. After several attempts at cardiopulmonary resuscitation, a decision was made to cease further resuscitation and she was pronounced deceased.

On histopathological examination ([Fig. 3](#fig3){ref-type="fig"}), the tumour was a conventional osteoblastic osteosarcoma with a high-grade component. The tumour arose from the cortical bone of the skull and invaded into the adjacent skeletal muscle and brain parenchyma. It contained large areas of malignant osteoid and small areas of atypical chondroid material. It was moderately to markedly hypercellular and was composed of cells with an epithelioid to spindled appearance. The nuclei were markedly pleomorphic with hyperchromatic, irregularly shaped nuclei and coarse chromatin. Many multinucleated forms were present. Numerous mitoses, including atypical form were seen. Lymphovascular invasion was seen. Immunohistochemistry results were consistent with an osteosarcoma, with the lesion being negative for melanocytic markers (Mart-1, HMB45 and SOX10), myogenic markers (desmin and myogenin), a vascular marker (ERG), an epithelial marker (pancytokeratin), a glial marker (GFAP) and a marker for solitary fibrous tumour (STAT6). Figure 3(A) The tumour contained lace-like areas of partly-calcified osteoid and intervening malignant osteoblasts. (B) The tumour cell nuclei were markedly enlarged, hyperchromatic and pleomorphic, and many were multinucleated. (C) The tumour is seen invading adjacent brain parenchyma (lower right of image).

Discussion
==========

Radiotherapy is an effective treatment for corticotroph tumours with incomplete resection or hormonal control after primary surgery, resulting in normalisation of hypercortisolism in 54--75% of cases ([@bib8]). Compared to conventional EBRT, newer techniques of stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) have refinements in patient immobilisation, imaging and dose distribution, thus delivering more localised radiation ([@bib9]). Nevertheless, complications of modern radiotherapy include hypopituitarism in up to 30--60% of patients by 10 years post-treatment and, less commonly, radiation-induced optic neuropathy, stroke and secondary tumours in 0--3% of cases ([@bib9]). Ionising radiation causes double-strand DNA damage and genomic instability, thereby increasing the risk of secondary malignancy ([@bib10]). Mutations of the p53 tumour suppressor gene, upregulated in response to DNA damage, are also more common in radiation-induced sarcomas than sporadic soft-tissue sarcomas ([@bib10]). The risk of radiotherapy-induced secondary brain tumours in individuals with pituitary tumours has been reported variably in the literature. An earlier cohort of 336 patients who received radiotherapy following pituitary surgery between 1962 and 1986 demonstrated a cumulative risk of secondary brain tumour of 1.9% at 20 years (95% CI: 0.7--5.0%), with a relative risk of 9.38 (95% CI: 3.05--21.89) compared to the normal population ([@bib11]). This study was extended for an additional 10 years with further recruitment and confirmed a cumulative risk of 2.4% at 20 years (95% CI: 1.2--5.0%) ([@bib11]). Meningiomas and high-grade astrocytomas were the most common secondary brain tumours, and only one patient developed a sarcoma ([@bib11]). However, a different cohort of 462 patients who received radiotherapy between 1956 and 2008 did not report an increased incidence of either intracranial or extracranial tumours, or overall mortality ([@bib4]). Pituitary tumours themselves are not thought to be associated with an increased risk of other malignancy, except in the case of growth-hormone secreting tumours and those with a hereditary cancer syndrome such as multiple endocrine neoplasia type 111 ([@bib12]). Although not proven, immunosuppression due to hypercortisolism in Cushing's disease has been proposed as a contributor to secondary tumour development ([@bib12]).

Criteria for the diagnosis of a radiation-induced sarcoma has been proposed and include the following: (1) presence of non-malignancy or malignancy of a different histological type before irradiation, (2) development of sarcoma within or adjacent to the path of the radiation beam, (3) latency period of at least 3 years between irradiation and diagnosis of secondary tumour, and (4) histological diagnosis of secondary sarcoma ([@bib13]). Our patient fulfilled all the criteria for a radiation-induced sarcoma, with histopathology confirming an osteosarcoma. The most common histological subtypes of radiation-induced sarcoma of the bone include osteosarcoma, followed by spindle-cell sarcoma, malignant fibrous histiocytoma and leiomyosarcoma ([@bib14]). The risk of radiation-induced osteosarcoma following radiotherapy is exceedingly rare, occurring in 0.01--0.03% of all irradiated patients, and observed more commonly in malignant indications for radiotherapy ([@bib15]). They account for 5.5% of all osteosarcomas and behave more aggressively than primary osteosarcomas ([@bib15]). Although the term implies the causative role of radiation in tumourigenesis, the contributory effects of genetic predisposition or concurrent chemotherapy in oncology indications should not be undermined ([@bib10]). The risk of radiation-induced sarcomas increases with dose and field size, with the minimum and median dose of cumulative radiation thought to cause a secondary sarcoma estimated to be 20 and 50 Gy, respectively ([@bib14]). Our patient received 5000 rad, equivalent to 50 Gy, through EBRT and thus the field size was significantly larger than one would expect with a modern stereotactic treatment. The risk of secondary malignancy with SRS is thought to be much lower than conventional EBRT, with an estimated cumulative incidence of 0.00045% over 10 years (CI 0.00--0.0034%) ([@bib16]). However, it should be noted that long-term follow-up data for patients receiving SRS are shorter than that of ERBT and thus definitive conclusions cannot be made at this stage.

Oncological literature from non-pituitary cases sheds some light on the association of radiation-therapy exposure and secondary malignancies. A review of 42 radiation-induced sarcomas of the bone with primary malignant indications showed a mean latent interval of 17 years (4--50) with a median dose of radiotherapy of 50 Gy (20--66) ([@bib14]).

The prevalence of radiation-induced osteosarcoma and other sarcomas of the skull in patients with prior radiotherapy for pituitary tumours has not been established and is largely described through case reports. Secondary tumours may arise in bone at the borders of the radiation field, where the radiation dose was sufficient to cause malignant transformation but insufficient to cause cell death ([@bib17]). [Table 1](#tbl1){ref-type="table"} describes the characteristics of nine other cases of radiation-induced osteosarcoma following pituitary tumour irradiation. The mean age at diagnosis of secondary tumour was 50 years (16--75) with a mean latency period of 13 years (5--22). At 30 years, this is the longest reported duration between radiotherapy for a pituitary tumour and development of a radiation-induced osteosarcoma in the literature. The sites of osteosarcoma in reported cases were divided between the skull and base of skull. Complete surgical excision, while the treatment of choice, was often ineffective due to tumour adherence and invasion of surrounding structures ([@bib12], [@bib14]). Chemotherapy was offered as either curative or palliative intent and involved standard bone sarcoma regimens such as doxorubicin, cisplatin and methotrexate ([@bib10]). Further radiotherapy is usually not advisable due to limits of normal tissue tolerance from prior irradiation ([@bib10]). One case report demonstrated the efficacy of Cyber-knife treatment to a base of skull radiation-induced osteosarcoma with complete resolution of neurological symptoms for over 24 months ([@bib18]). Most cases had short survival periods. Literature also affirms an overall poor prognosis, with a 5-year disease-free survival time of 17% and median survival of 8.8 months in palliative cohorts ([@bib14], [@bib15]). Table 1Case reports of radiation-induced osteosarcoma following pituitary tumour irradiation. Our case is included for comparison.Author, yearAgeRadiation doseLatency (years)Site of osteosarcomaTreatmentPrognosisMeredith *et al*. (19)572052 rad6Temporal boneSurgeryVery shortSparagana *et al*. (20)507750 rad21Frontal boneSurgery5 monthsAmine & Sugar (22)1651 Gy10SellaRadiation5 weeksSugita *et al*. (21)655000 rad7Frontotemporal boneSurgery, chemotherapy-Salvati *et al*. 23)4544 Gy12SphenoidRadiation16 monthsGnanalingham *et al*. (24)6752 Gy14SellaSurgery-Hansen & Moffat (25)295000 rad22Sphenoid, frontal clivusChemotherapyVery shortBembo *et al*. (26)4546 Gy5SellaSurgery7 weeksYamada *et al*. (12)7550 Gy20Sphenoid sinusCyberknife surgery, chemotherapy\>24 monthsThis case report675000 rad30Temporal boneSurgeryDays[^1]

Our case highlights a rare but devastating long-term complication of pituitary tumour irradiation. Radiation-induced osteosarcomas can arise in either the base of skull or the calvarium, as in this case. These tumours by definition occur years after primary irradiation with a dose-dependent increase in risk. Management consists of surgical resection followed by systemic chemotherapy, although patients often present with advanced disease unamenable to treatment, with poor outcome. Long-term follow-up studies on patients receiving SRS or FSRT are warranted to examine the risk of development of such tumours.
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